Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Hedy Lee Kindler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5450-842X; OpenAlex author ID A5090156519. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 4, last author 7)
Trials
7 (principal investigator on 5)
Grants
0
Labs led
2
Collaborators
157
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: 1 trial · 2003: 1 trial · 2004: 2 trials · 2005: none · 2006: none · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 6 papers, 1 trial · 2013: 5 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 6 papers · 2019: 6 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper

Papers 37

  1. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  2. Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Co-author DOI 10.1002/cncr.34610↗
  3. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Co-author DOI 10.1093/oncolo/oyad080↗
  4. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1200/po.22.00196↗
  5. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  6. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… First author DOI 10.1200/jco.19.01890↗
  7. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. Last author DOI 10.21037/jgo-20-187↗
  8. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Last author DOI 10.1056/nejmoa1903387↗
  9. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. First author DOI 10.1093/annonc/mdz406↗
  10. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Co-author DOI 10.1097/fpc.0000000000000375↗
  11. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  12. Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1541-7786.mcr-18-0531↗
  13. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  14. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  15. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Last author DOI 10.1002/jso.24872↗
  16. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. Co-author DOI 10.1016/j.jgo.2018.03.002↗
  17. A Glimmer of Hope for Pancreatic Cancer. Co-author DOI 10.1056/nejme1813684↗
  18. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Co-author DOI 10.1080/15384047.2017.1416937↗
  19. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  20. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Co-author DOI 10.1038/bjc.2017.19↗
  21. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  22. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000458↗
  23. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Last author DOI 10.1200/jco.2015.62.8719↗
  24. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). Co-author DOI 10.1093/jnci/dju185↗
  25. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Last author DOI 10.14694/edbook_am.2014.34.e157↗
  26. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastat… Co-author DOI 10.1007/s11136-012-0217-4↗
  27. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Co-author DOI 10.1158/1078-0432.ccr-12-1840↗
  28. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Co-author DOI 10.1158/1078-0432.ccr-13-0926↗
  29. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcino… Last author DOI 10.1186/2051-1426-1-8↗
  30. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  31. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 8030… Co-author DOI 10.1002/cncr.26270↗
  32. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Co-author DOI 10.1007/s10637-010-9526-z↗
  33. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the… First author DOI 10.1016/j.jpainsymman.2011.09.001↗
  34. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic panc… Co-author DOI 10.1093/annonc/mds142↗
  35. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Co-author DOI 10.1158/1078-0432.ccr-11-1387↗
  36. A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. Co-author DOI 10.14694/edbook_am.2012.32.173↗
  37. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗

Trials 7

  1. Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Principal investigator NCT01643499↗
  2. Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Principal investigator NCT01064622↗
  3. Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer Principal investigator NCT00091026↗
  4. Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT00095966↗
  5. Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine Study chair NCT00053222↗
  6. Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer Principal investigator NCT00028834↗
  7. Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer Study chair NCT00003677↗

Closest collaborators

The 25 strongest of 157 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Talia Golan · 7 shared papers, 2017–2023 · strength 0.69
  2. Eileen Mary O'Reilly · 8 shared papers, 2012–2022 · strength 0.54
  3. Eric Van Cutsem · 5 shared papers, 2011–2022 · strength 0.38
  4. Daniel Hochhauser · 4 shared papers, 2019–2022 · strength 0.36
  5. Dirk Arnold · 4 shared papers, 2019–2022 · strength 0.36
  6. Michele Reni · 4 shared papers, 2019–2022 · strength 0.36
  7. Pascal R. Hammel · 4 shared papers, 2019–2022 · strength 0.36
  8. Teresa Mercade Macarulla · 4 shared papers, 2019–2022 · strength 0.36
  9. Michael J. Hall · 4 shared papers, 2012–2022 · strength 0.32
  10. Mitchell C. Posner · 4 shared papers, 2013–2020 · strength 0.30
  11. Alan Paul Venook · 7 shared papers, 2012–2018 · strength 0.29
  12. Joon Oh Park · 3 shared papers, 2019–2022 · strength 0.29
  13. Zev A. Wainberg · 2 shared papers, 2019–2025 · strength 0.28
  14. Hyun Kyoo Yoo · 2 shared papers, 2019–2023 · strength 0.28
  15. Jordan D. Berlin · 3 shared papers, 2013–2023 · strength 0.28
  16. Do‐Youn Oh · 3 shared papers, 2019–2022 · strength 0.27
  17. Giampaolo Tortora · 3 shared papers, 2019–2022 · strength 0.27
  18. Anke Reinacher‐Schick · 3 shared papers, 2019–2022 · strength 0.27
  19. Hana Algül · 3 shared papers, 2019–2022 · strength 0.27
  20. Christine M. Drogan · 1 shared paper, 2023 · strength 0.26
  21. Sonia S. Kupfer · 1 shared paper, 2023 · strength 0.26
  22. Vincent J. Picozzi · 2 shared papers, 2019–2023 · strength 0.24
  23. Kevin King Roggin · 3 shared papers, 2018–2019 · strength 0.24
  24. Kouros Owzar · 5 shared papers, 2012–2019 · strength 0.23
  25. Chen Jiang · 5 shared papers, 2012–2019 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.